contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dignitana-ab-dignitana-expands-partnership-with-celeritas-to-improve-scalp-cooling-technology-available-in-mexico

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Dignitana

Dignitana AB (http://www.dignitana.com), manufacturer of The DigniCap® Scalp Cooling System, has expanded the agreement with Celeritas Trading (https://celeritasmexico.com/) to provide The DigniCap...

<div class="abstract">Dignitana AB&nbsp;(<a href="http://www.dignitana.com">http://www.dignitana.com</a>), manufacturer of The DigniCap® Scalp Cooling System, has expanded the agreement with Celeritas Trading&nbsp;(<a href="https://celeritasmexico.com/">https://celeritasmexico.com/</a>) to provide The DigniCap Delta model of the DigniCap Scalp Cooling System to minimize hair loss from chemotherapy for cancer patients in Mexico. &nbsp;</div>With the introduction of the DigniCap Delta model, patients will now have access to the next generation in scalp cooling technology - the thermoelectric cooling system and custom fit cooling wrap that is offered with the DigniCap Delta model.Celeritas Trading has been Dignitana's exclusive distributor in Mexico since 2009, currently offering DigniCap C3 at nine locations across the country. Celeritas has now purchased two DigniCap Delta devices."We are delighted to expand our offering in Mexico to now provide the most advanced scalp cooling technology available," said Catarina Löwenadler, CEO of Dignitana.&nbsp; "Celeritas has been a strong partner to Dignitana and we are pleased that patients in Mexico now have access to this latest technology to preserve dignity and quality of life during chemo.""The decision to transition from DigniCap C3 to DigniCap Delta was driven by patient demand for a clinically superior product," said Susana Valdez, Principal of Celeritas Trading. "Hair loss during chemo impacts quality of life, and patients in Mexico want this life-changing therapy."DigniCap Delta is indicated for use with solid tumor cancers, and of these, Breast Cancer is the most prevalent globally. Breast cancer is the second most common cancer in Mexico with over 30,000 new diagnoses each year. It accounts for 10.6% of all cancers and 16.4% of cancers in women in Mexico.

Dignitana AB: Dignitana expands partnership with Celeritas to improve scalp cooling technology available in Mexico